Lead Manager on Aquestive Therapeutics' Confidentially Marketed Public Offering

Oppenheimer & Co. Inc. acted as Lead Manager on Aquestive Therapeutics’ Confidentially Marketed Public Offering

Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a clinical stage pharmaceutical company providing novel alternatives to invasive and inconvenient standard of care therapies, announced on 3/19/24 the pricing of its underwritten public offering of 16,666,667 shares of its common stock at a price of $4.50 per share. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $75.0 million. Aquestive has granted the underwriters a 30-day option to purchase up to 2,500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system and an earlier stage pipeline for the treatment of severe allergic reactions. The Company has five commercialized products marketed by its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. Aquestive collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies and has proven drug development and commercialization capabilities. Aquestive expects to file an NDA for Anaphylm, the company’s first and only orally administered epinephrine prodrug product, before the end of 2024.